JNJ

238.68

-0.55%↓

UNH

274.9

-0.55%↓

TMO

546.83

+0.89%↑

ABT

111.08

+0.23%↑

ISRG

492.83

+1.14%↑

JNJ

238.68

-0.55%↓

UNH

274.9

-0.55%↓

TMO

546.83

+0.89%↑

ABT

111.08

+0.23%↑

ISRG

492.83

+1.14%↑

JNJ

238.68

-0.55%↓

UNH

274.9

-0.55%↓

TMO

546.83

+0.89%↑

ABT

111.08

+0.23%↑

ISRG

492.83

+1.14%↑

JNJ

238.68

-0.55%↓

UNH

274.9

-0.55%↓

TMO

546.83

+0.89%↑

ABT

111.08

+0.23%↑

ISRG

492.83

+1.14%↑

JNJ

238.68

-0.55%↓

UNH

274.9

-0.55%↓

TMO

546.83

+0.89%↑

ABT

111.08

+0.23%↑

ISRG

492.83

+1.14%↑

Search

ResMed Inc

Fechado

SetorSaúde

276.12 1.92

Visão Geral

Variação de preço das ações

24h

Atual

Mín

269.32

Máximo

276.39

Indicadores-chave

By Trading Economics

Rendimento

44M

393M

Vendas

87M

1.4B

P/E

Médio do Setor

25.197

84.243

Rendimento de Dividendos

0.87

Margem de lucro

27.593

Funcionários

10,600

EBITDA

63M

566M

Recomendações

By TipRanks

Recomendações

Comprar

Previsão para 12 meses

+10.68% upside

Dividendos

By Dow Jones

Rendimento de Dividendos

Médio do Setor

0.87%

2.28%

Próximos Ganhos

22 de abr. de 2026

Próxima data de dividendos

19 de mar. de 2026

Próxima data de ex-dividendo

12 de fev. de 2026

Estatísticas de Mercado

By TradingEconomics

Capitalização de Mercado

-107M

37B

Abertura anterior

274.2

Fecho anterior

276.12

Sentimento de Notícias

By Acuity

14%

86%

15 / 352 Ranking em Healthcare

ResMed Inc Gráfico

O desempenho passado não é um indicador confiável de resultados futuros.

Notícias Relacionadas

9 de fev. de 2026, 17:25 UTC

Aquisições, Fusões, Aquisições de Empresas

Eli Lilly to Buy Biotech Orna Therapeutics for Up to $2.4 Billion -- Update

9 de fev. de 2026, 23:46 UTC

Conversa de Mercado

Nikkei May Rise on Hopes for Domestic Policy Measures -- Market Talk

9 de fev. de 2026, 23:43 UTC

Conversa de Mercado

Gold Falls on Possible Technical Correction -- Market Talk

9 de fev. de 2026, 23:14 UTC

Conversa de Mercado

WiseTech's Bull Reckons AI-Driven Selloff Is Overdone -- Market Talk

9 de fev. de 2026, 22:29 UTC

Conversa de Mercado

Australian Coking Coal Price Seen Falling Once Supply Disruptions Ease -- Market Talk

9 de fev. de 2026, 22:19 UTC

Conversa de Mercado

Pro Medicus's Business Case Made More Compelling by AI Adoption -- Market Talk

9 de fev. de 2026, 22:08 UTC

Conversa de Mercado

Minerals 260 Bull Bets on Production Scale, Takeover Appeal -- Market Talk

9 de fev. de 2026, 22:01 UTC

Ganhos

Friedman Industries Sees 4Q Sales Volume to Generally Consistent With 3Q, With Sequential Improvement in Sales Margins

9 de fev. de 2026, 21:59 UTC

Ganhos

Friedman Industries: Hedging Activities Continued to Perform as Anticipated by Mitigating Impact of Commodity Price Volatility

9 de fev. de 2026, 21:59 UTC

Ganhos

Friedman Industries: Average Selling Prices Began to Improve as Quarter Progressed

9 de fev. de 2026, 21:58 UTC

Ganhos

Friedman Industries 3Q Sales $168M >FRD

9 de fev. de 2026, 21:50 UTC

Conversa de Mercado
Aquisições, Fusões, Aquisições de Empresas

Financial Services Roundup: Market Talk

9 de fev. de 2026, 21:50 UTC

Conversa de Mercado

Basic Materials Roundup: Market Talk

9 de fev. de 2026, 21:48 UTC

Ganhos

Friedman Industries 3Q EPS 43c >FRD

9 de fev. de 2026, 21:17 UTC

Ganhos

Kyndryl Stock Drops 55%. It's So Much Worse Than an Earnings Miss. -- Barrons.com

9 de fev. de 2026, 21:13 UTC

Conversa de Mercado

U.S. Ethanol Crush Margins Near Break-Even -- Market Talk

9 de fev. de 2026, 21:04 UTC

Ganhos

Retail Sales Data Should Confirm a Robust Holiday Season -- Barrons.com

9 de fev. de 2026, 20:30 UTC

Conversa de Mercado

Oil Futures Gain As U.S.-Iran Risk Premium Holds -- Market Talk

9 de fev. de 2026, 20:02 UTC

Conversa de Mercado

U.S. Natural Gas Falls on Warmer Weather Outlook -- Market Talk

9 de fev. de 2026, 19:42 UTC

Conversa de Mercado

Japan's Yield Curve Expected to Flatten -- Market Talk

9 de fev. de 2026, 19:31 UTC

Conversa de Mercado

Nike Seen Regaining Relevance With Consumers -- Market Talk

9 de fev. de 2026, 19:27 UTC

Conversa de Mercado

Gold Climbs Back Over $5,000/oz -- Market Talk

9 de fev. de 2026, 19:05 UTC

Conversa de Mercado

Nike Returns to List of Hottest Brands -- Market Talk

9 de fev. de 2026, 18:19 UTC

Conversa de Mercado

Lower Dollar Doesn't Translate to Boost in Grains -- Market Talk

9 de fev. de 2026, 17:41 UTC

Ganhos
Aquisições, Fusões, Aquisições de Empresas

These Stocks Are Today's Movers: Kyndryl, Hims & Hers, Novo Nordisk, AppLovin, Monday.com, Valaris, and More -- Barrons.com

9 de fev. de 2026, 17:31 UTC

Ganhos
Aquisições, Fusões, Aquisições de Empresas

These Stocks Are Today's Movers: Kyndryl, Hims & Hers, Novo Nordisk, Monday.com, Valaris, Cleveland-Cliffs, and More -- Barrons.com

9 de fev. de 2026, 17:20 UTC

Conversa de Mercado
Aquisições, Fusões, Aquisições de Empresas

Financial Services Roundup: Market Talk

9 de fev. de 2026, 17:20 UTC

Conversa de Mercado

Basic Materials Roundup: Market Talk

9 de fev. de 2026, 17:17 UTC

Conversa de Mercado

Century Aluminum Announces Next Steps of Okla. Project -- Market Talk

9 de fev. de 2026, 17:16 UTC

Ganhos

Kyndryl Stock Drops 56%. It's So Much Worse Than an Earnings Miss. -- Barrons.com

Comparação entre Pares

Variação de preço

ResMed Inc Previsão

Preço-alvo

By TipRanks

10.68% parte superior

Previsão para 12 meses

Média 300.64 USD  10.68%

Máximo 345 USD

Mínimo 265 USD

Com base em 13 analistas de Wall Street que oferecem metas de preço de 12 meses para ResMed Inc - Dist nos últimos 3 meses.

Consenso de Avaliação

By TipRanks

Comprar

13 ratings

8

Comprar

5

Manter

0

Vender

Sentimento

By Acuity

15 / 352 Ranking em Saúde

Sentimento de Notícias

Evidência Muito Forte de Tendência de Alta

Volatilidade

Abaixo da média

Volume de Notícias (RCV)

Abaixo da média

Informação Financeira

Custos administrativos e de venda

Custos Operacionais

Lucro antes de imposto

Vendas

Custo das vendas

Lucro bruto sobre vendas

Despesa com juros da dívida

EBITDA

Resultado Operacional

$

Sobre ResMed Inc

ResMed Inc. develops, manufactures, distributes, and markets medical devices and cloud-based software applications for the healthcare markets. The company operates in two segments, Sleep and Respiratory Care, and Software as a Service. It offers various products and solutions for a range of respiratory disorders, including ApneaLink Air, a portable diagnostic device that measures oximetry, respiratory effort, pulse, nasal flow, and snoring; and NightOwl, a portable, cloud-connected, and disposable diagnostic device that measures AHI based on derived peripheral arterial tone, actigraphy, and oximetry over several nights. The company also provides AirView, a cloud-based system that enables remote monitoring and changing of patients' device settings; myAir, a personalized therapy management application for patients with sleep apnea that provides support, education, and troubleshooting tools for increased patient engagement and improved compliance; U-Sleep, a compliance monitoring solution that enables home medical equipment (HME) to streamline their sleep programs; connectivity module and propeller solutions; and Propeller portal. It offers out-of-hospital software solution, such as Brightree business management software and service solutions to providers of HME, pharmacy, home infusion, orthotics, and prosthetics services; MatrixCare care management and related ancillary solutions to senior living, skilled nursing, life plan communities, home health, home care, and hospice organizations, as well as related accountable care organizations; HEALTHCAREfirst that offers electronic health record, software, billing and coding services, and analytics for home health and hospice agencies; and MEDIFOX DAN's software solutions. The company markets its products to sleep clinics, home healthcare dealers, and hospitals through a network of distributors and direct sales force. ResMed Inc. was founded in 1989 and is headquartered in San Diego, California.
help-icon Live chat